Discovery of new drugs in thoracic oncology

Anne-Marie Dingemans (Masstricht, Netherlands)

Source: International Congress 2016 – Molecular footprints in lung cancer diagnosis and management
Session: Molecular footprints in lung cancer diagnosis and management
Session type: Symposium
Number: 1948

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Anne-Marie Dingemans (Masstricht, Netherlands). Discovery of new drugs in thoracic oncology. International Congress 2016 – Molecular footprints in lung cancer diagnosis and management

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Challenges and controversies in thoracic oncology: a new ERJ series
Source: Eur Respir J 2014; 43: 1571-1572
Year: 2014


Immunotherapy: a new standard of care in thoracic malignancies?
Source: Eur Respir J, 51 (2) 1702072; 10.1183/13993003.02072-2017
Year: 2018



Perspectives on the new drugs pipeline
Source: School Course 13
Year: 2013


Lung cancer classification and characterisation in daily practice of thoracic oncology
Source: International Congress 2014 – The more in-depth classification of lung cancer: relevance for patients and science
Year: 2014

The HERMES curriculum for thoracic oncology: the first step to a pan-European thoracic oncology exam
Source: International Congress 2014 – The importance of multidisciplinary approaches to lung cancer treatment
Year: 2014

Human translational medicine in ILD: the promise of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

Rationale and targets of immunotherapy in thoracic malignancies
Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies?
Year: 2016


The thoracic oncology specialist: curriculum recommendations in thoracic oncology training
Source: Eur Respir J 2016; 48: 628-631
Year: 2016


Assembly 11: thoracic oncology
Source: Breathe, 14 (2) 163; 10.1183/20734735.016918
Year: 2018



Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014

New frontiers: NIV in oncology and palliation
Source: School Course 2012 - ERS School Course on Noninvasive Positive Pressure Ventilation
Year: 2012



Multidisciplinary team management in thoracic oncology: more than just a concept?
Source: Eur Respir J 2014; 43: 1776-1786
Year: 2014



Development of a novel nano-sized carrier system for aeroseol drug delivery (EGE University translational pulmonology research group)
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015

The future is here in thoracic oncologic imaging: role of radiogenomics
Source: Virtual Congress 2020 – Imaging grand round
Year: 2020


Clinical nurse specialist led image guided pleural interventions – Is it safe?
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015


Updates in oncology
Source: Annual Congress 2013 –Ceremony for the ERS Romain Pauwels Research Award (financially supported by GlaxoSmithKline) followed by Clinical Year in Review II
Year: 2013


Updates in oncology
Source: Eur Respir Rev 2014; 23: 69-78
Year: 2014



Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology
Source: Breathe 2016; 12: 249-255
Year: 2016


Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008